



Irish Blood Transfusion Service

Seirbhís Fuilaidriúcháin na hÉireann

Document Detail

Type: PMF IBTS SPEC
Document No.: IBTS/PMF/SPEC/0204[2]
Title: **WHOLE BLOOD AUTOLOGOUS**
Owner: 1066 KATE FITZGERALD
Status: CURRENT
Effective Date: 06-Aug-2015
Expiration Date:

Review

Review: IBTS PMF REVIEW

<u>Level</u>	<u>Owner Role</u>	<u>Actor</u>	<u>Sign-off By</u>
1	DIRECTOR OF QUALITY	MARIE O'CONNELL	MARIE O'CONNELL
1	NATIONAL MEDICAL DIRECTOR	WILLIAM MURPHY	WILLIAM MURPHY
1	LABS HEAD OF PROCESSING IBTS	BERNIE QUIRKE	BERNIE QUIRKE
1	QUALITY MANAGER MRTC	COLIN JOHNS	COLIN JOHNS

Change Orders

Changes as described on Change Order: Change Order No.

Change Orders - Incorporated

Changes as described on Change Order: Change Order No.
IBTS/CO/0329/15

IRISH BLOOD TRANSFUSION SERVICE**PRODUCT MASTER FILE**

Title : Whole Blood Autologous

Name of Product: WHOLE BLOOD for Autologous Transfusion (CPDA1)

E Progesa Codabar Component Code : 30002

E Progesa ISBT-128 Component Code : E4396100

General Description: Unit of whole blood collected for the **sole purpose** of re-infusion into the donor, if required. The removal of the majority of leucocytes is achieved by filtration.

General Specification: Autologous donations shall be identified, collected, processed and verified as to quality according to Standard Operating Procedures for homologous blood donations.

Storage: Whole Blood, Leucodepleted for Autologous Transfusion should be stored at $4^{\circ}\text{C} \pm 2^{\circ}\text{C}$. Autologous blood and blood components must be stored separately. The storage time is 35 days.

Labelling: See Appendix 1

Transportation: The air temperature of the validated transport containers for units of Whole Blood for autologous transfusion should be maintained between 2°C and 10°C during transport from the Irish Blood Transfusion Service to the place that they are intended for use. Transport time under these conditions normally should not exceed 8 hours.

Indications for Use:

- Whole blood for autologous transfusion can be used in selected elective surgical patients.
- Whole blood for autologous transfusion can also be considered for individuals with rare blood groups or with rare or multiple red cell antibodies.

Precautions in Use:

- Careful selection of appropriate patients is an important part of a safe and successful autologous pre-deposit programme.
- One or more venesections over a period of weeks may result in morbidity which needs to be balanced against the potential risks of receiving blood from volunteers.
- Careful attention to documentation is essential to reduce the risk of a clerical error which may lead to a haemolytic transfusion reaction.
- Pre-deposited blood should be transfused using similar clinical indications to those for allogeneic transfusion; it should not be transfused simply because it is available.
- Whole blood should be infused intravenously through a set containing an inline 170-200 µm filter.

Adverse Effects:

- Acute sepsis due to bacterial contamination.
- Autologous transfusions are also susceptible to adverse events such as acute haemolytic transfusion reactions that arise from errors in patient/recipient identification, and from failure to store the product within specified parameters.

Serious Adverse Reaction

Serious adverse reactions should be reported to:

National Haemovigilance Office
Irish Blood Transfusion Service
National Blood Centre
James's Street
Dublin 8

AND

Quality Assurance Manager
Irish Blood Transfusion Service

AT EITHER

National Blood Centre
James's Street
Dublin 8

OR

St Finbarr's Hospital
Douglas Road
Cork.

APPENDIX 1

E Progesa Codabar Component Code: 30002

E Progesa ISBT -128 Component Code: E4396100

Product Name:
WHOLE BLOOD for Autologous
Transfusion (CPDA1)

Shelf Life:
35 days

Additional Tag containing the following data:

Side 1

Donor's name
Address
Date of Birth

Side 2

Unit Number
Name of admitting hospital
Donor's Signature
Medical Officer's Signature

Labelling and Barcodes:

(for illustration purposes only – barcodes not suitable for scanning – label not to scale)

IBTS ver 1.0

WHOLE BLOOD for Autologous Transfusion (CPDA1)

Store at 4°C ± 2°C

Drawn 21 July 2015

450 ml

Expiry 25 Aug 2015 23:59

30002

Expiry 25/08/2015

O Pos

Rh D Positive

This component must not be used if there are visible signs of deterioration. This component may transmit infection. Must be administered using a suitable transfusion set incorporating a 170 - 200 µm filter. Collected into 66 ml of CPDA1 anticoagulant containing:
Citric Acid 16, Sodium Citrate 88, Sodium dihydrogen phosphate 18, Glucose 161, Adenine 2.